What is the INCY stock price?

Incyte Genomics Inc (INCY) latest quote: $115.89, as of 10/27/26 1:07 PM ET. Prices on Cylvex may be delayed.

How many analyst price targets for INCY were reached?

28 of 38 published price targets for INCY were reached within 12 months (74% reached); 19 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on INCY?

25 firms have published price targets or ratings on INCY that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

INCY

Incyte Genomics Inc · NASDAQ

$115.89USDCS band Balanced

↑ $2.58 (2.27%) Today

As of Oct 27, 1:07 PM ET · May be delayed

Daily prices

Mkt Cap

$23.5B

Volume

1.8M

52W High

$132.60

52W Low

$84.02

PE Ratio

14.6

Avg Vol

1.8M

As of 10/26/26

Div Yield

—

Beta

0.38

As of 10/26/26

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Sentiment

No sentiment yet

At least 5 tagged posts are needed.

How do you feel about INCY?

Latest news

News ›

Zacks Investment Research9/30/26

INCY or TECH: Which Is the Better Value Stock Right Now?

A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.

TECH

Headlines link to the publisher. Not investment advice.

Board · 0 threads

Open board ›

No threads yet

Cylvex posts are automated counts of published analyst actions, not opinions. Not investment advice.